Page 59 - TD-2-2

Tumor Discovery Choroid plexus tumors: Benign to malignant

12(2): 158. https://doi.org/10.1007/S00262-014-1635-7
https://doi.org/10.3390/PHARMACEUTICS12020158 154. Calderwood SK, Theriault JR, Gong J, 2005, Message in a
bottle: Role of the 70-kDa heat shock protein family in anti-
145. Golubovskaya V, 2022, CAR-T cells targeting immune
checkpoint pathway players. Front Biosci (Landmark Ed), tumor immunity. Eur J Immunol, 35(9): 2518–2527.
27(4): 121. https://doi.org/10.1002/EJI.200535002
https://doi.org/10.31083/J.FBL2704121 155. Shevtsov MA, Kim AV, Samochernych KA, et al., 2014, Pilot
study of intratumoral injection of recombinant heat shock
146. Vitanza NA, Johnson AJ, Wilson AL, et al., 2021, protein 70 in the treatment of malignant brain tumors in
Locoregional infusion of HER2-specific CAR T cells in children. Onco Targets Ther, 7: 1071–1081.
children and young adults with recurrent or refractory CNS
tumors: An interim analysis. Nat Med, 27(9): 1544–1552. https://doi.org/10.2147/OTT.S62764
https://doi.org/10.1038/S41591-021-01404-8 156. Bernstock JD, Kang KD, Klinger NV, et al., 2022, Targeting
oncometabolism to maximize immunotherapy in malignant
147. NCT03173950, 2023, Immune Checkpoint Inhibitor brain tumors. Oncogene, 41(19): 2663–2671.
Nivolumab in People with Recurrent Select Rare CNS
Cancers - Full Text View - ClinicalTrials.gov. Available from: https://doi.org/10.1038/s41388-022-02312-y
https://clinicaltrials.gov/ct2/show/NCT03173950 [Last 157. Choi EJ, Sloma EA, Miller AD, 2016, Kir7.1 immunoreactivity
accessed on 2023 May . in canine choroid plexus tumors. J Vet Diagn Invest, 28(4):
25]
148. NCT03638167, 2023, EGFR806-specific CAR T Cell 464–468.
Locoregional Immunotherapy for EGFR-positive https://doi.org/10.1177/1040638716650239
Recurrent or Refractory Pediatric CNS Tumors - Full
Text View - ClinicalTrials.gov. Available from: https:// 158. Reginato A, Girolami D, Menchetti L, et al., 2016, E-cadherin,
clinicaltrials.gov/ct2/show/NCT03638167 [Last accessed on N-cadherin expression and histologic characterization of
2023 May . canine choroid plexus tumors. Vet Pathol, 53(4): 788–791.
25]
149. NCT04185038, 2023, Study of B7-H3-Specific CAR T https://doi.org/10.1177/0300985815620844
Cell Locoregional Immunotherapy for Diffuse Intrinsic 159. NCT04105374, 2023, Testing the Addition of an Anti-
Pontine Glioma/Diffuse Midline Glioma and Recurrent or cancer Viral Gene Therapy, Toca 511/Toca FC, to
Refractory Pediatric Central Nervous System Tumors - Full the Usual Treatment (Temozolomide and Radiation
Text View - ClinicalTrials.gov. Available from: https:// Therapy) for Newly Diagnosed Glioblastoma - Full
clinicaltrials.gov/ct2/show/NCT04185038 [Last accessed on Text View - ClinicalTrials.gov. Available from: https://
2023 May . clinicaltrials.gov/ct2/show/NCT04105374 [Last accessed
25]
on 2023 May .
25]
150. NCT03500991, 2023, HER2-specific CAR T Cell
Locoregional Immunotherapy for HER2-positive 160. Ghajar-Rahimi G, Kang KD, Totsch SK, et al., 2022, Clinical
Recurrent/Refractory Pediatric CNS Tumors - Full advances in oncolytic virotherapy for pediatric brain tumors.
Text View - ClinicalTrials.gov. Available from: https:// Pharmacol Ther, 239: 108193.
clinicaltrials.gov/ct2/show/NCT03500991 [Last accessed on https://doi.org/10.1016/j.pharmthera.2022.108193
25]
2023 May .
161. Gállego Pérez-Larraya J, García-Moure M, Alonso MM,
151. Tatum AM, Mylin LM, Bender SJ, et al., 2008, CD8+ T cells 2023, Oncolytic virotherapy for the treatment of pediatric
targeting a single immunodominant epitope are sufficient brainstem gliomas. Rev Neurol (Paris), 179(5): 475–480.
for elimination of established SV40 T antigen-induced brain
tumors. J Immunol, 181(6): 4406–4417. https://doi.org/10.1016/j.neurol.2023.03.016
https://doi.org/10.4049/jimmunol.181.6.4406 162. Wang S, Yin Y, Liu S, 2019, Roles of microRNAs during
glioma tumorigenesis and progression. Histol Histopathol,
152. Schell TD, Tevethia SS, 2001, Control of advanced choroid 34(3): 213–222.
plexus tumors in SV40 T antigen transgenic mice following
priming of donor CD8(+) T lymphocytes by the endogenous https://doi.org/10.14670/HH-18-040
tumor antigen. J Immunol, 167(12): 6947–6956. 163. Ghaemmaghami AB, Mahjoubin-Tehran M,
Movahedpour A, et al., 2020, Role of exosomes in malignant
https://doi.org/10.4049/jimmunol.167.12.6947
glioma: MicroRNAs and proteins in pathogenesis and
153. Cozza EM, Cooper TK, Budgeon LR, et al., 2015, Protection diagnosis. Cell Commun Signal, 18(1): 1–19.
from tumor recurrence following adoptive immunotherapy
varies with host conditioning regimen despite initial https://doi.org/10.1186/S12964-020-00623-9/tables/2
regression of autochthonous murine brain tumors. Cancer 164. Katsila T, Kardamakis D, 2021, The role of microRNAs in
Immunol Immunother, 64(3): 325–336. gliomas - therapeutic implications. Curr Mol Pharmacol,

Volume 2 Issue 2 (2023) 17 https://doi.org/10.36922/td.1057